Chardan Capital assumed coverage on shares of Gossamer Bio (NASDAQ:GOSS – Free Report) in a report published on Tuesday, MarketBeat.com reports. The brokerage issued a buy rating on the stock.
Other analysts have also issued research reports about the company. HC Wainwright reaffirmed a “buy” rating on shares of Gossamer Bio in a report on Thursday, August 27th. Leerink Partners upgraded Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 price target for the company in a report on Tuesday, July 28th. Weiss Ratings upgraded Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 9th. Finally, Wall Street Zen cut Gossamer Bio from a “hold” rating to a “sell” rating in a research report on Sunday, September 20th. Five equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $256.00.
Get Our Latest Research Report on Gossamer Bio
Gossamer Bio Price Performance
NASDAQ GOSS opened at $8.89 on Tuesday. Gossamer Bio has a twelve month low of $8.73 and a twelve month high of $309.60. The stock has a 50-day simple moving average of $12.03 and a 200 day simple moving average of $16.95.
Hedge Funds Weigh In On Gossamer Bio
Hedge funds have recently modified their holdings of the stock. Corient Private Wealth LP boosted its stake in Gossamer Bio by 41.3% in the 2nd quarter. Corient Private Wealth LP now owns 5,632,698 shares of the company’s stock valued at $927,000 after buying an additional 1,647,315 shares in the last quarter. Hsbc Holdings PLC raised its stake in Gossamer Bio by 1,289.4% during the second quarter. Hsbc Holdings PLC now owns 1,583,118 shares of the company’s stock worth $267,000 after acquiring an additional 1,469,175 shares in the last quarter. Bank of America Corp DE acquired a new position in Gossamer Bio during the second quarter worth $65,000. Hhlr Advisors LTD. acquired a new position in Gossamer Bio during the second quarter worth $819,000. Finally, ARCH Venture Management LLC acquired a new position in Gossamer Bio during the second quarter worth $1,326,004. 81.23% of the stock is owned by institutional investors and hedge funds.
About Gossamer Bio
Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with disorders involving the immune system, inflammation and fibrosis. The company is headquartered in San Diego, California, and primarily operates through the development of its proprietary drug candidates and strategic collaborations.
Gossamer’s lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways associated with pulmonary vascular remodeling.
Further Reading
- Five stocks we like better than Gossamer Bio
- ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing
- Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans
- AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle
- Beyond the GPU: Credo Paves the Next AI Data Superhighway
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.
